Evaluation Of The RDW Index (Red Cell Distribution Width) In The Prognosis Of Patients With Breast Cancer

Abstract

Abstract Background: Breast cancer is the most common cancer and the most frequent cause of death in women. The tumor inflammatory process is associated with the initiation, progression and maintenance of cancer and Red cell distribution width (RDW) index is one of the parameters that is altered in progressive inflammatory states. Objective: To correlate RDW and inflammatory markers in women with breast cancer as aid in monitoring adverse events associated with the use of doxorubicin. Methods: Database analysis of a prospective study of 80 women with breast malignancy undergoing doxorubicin-based chemotherapy, in a public hospital, from June 2015 to June 2018. To assess the significance of RDW in cancer and to correlate it with the variables: - plasma levels of C-reactive protein (CRP), galectin 3, myeloperoxidase, NT-terminal B-type natriuretic peptide and troponin I (cTnI). Results: Analysis by marginal logistic regression, significant differences were found over time for the variables - RDW (p<0.001), PCR (p=0.036). In the comparative analysis of correlation between the different variables, there was a significant, negative difference between RDW and CRP at time T1, with a decrease in CRP over time, while RDW showed an increase. Conclusion: The RDW is a simple test, easy to obtain and economical as part of the hemogram. The present study presented significant differences in providing additional information regarding the laboratory evolution of breast cancer and variations in its evolution regarding the therapeutic response.